Santosh Aryal

Dr. Santosh Aryal is an Associate Professor in the Department of Pharmaceutical Science and Health Outcomes at the University of Texas at Tyler (UT-Tyler). He holds a Ph.D. in Bionanosystem Engineering from Chonbuk National University, South Korea, and has held prior appointments at institutions including the University of California, San Diego, and Houston Methodist Research Institute. His primary research focuses on nanomedicine, particularly in designing nanoparticle-based systems for targeted drug delivery, photothermal therapy, and imaging applications in cancer and vascular diseases. Dr. Aryal's work emphasizes biomimetic approaches, leveraging extracellular vesicles and bioengineered membranes to enhance therapeutic efficacy and reduce off-target effects.

Dr. Aryal's academic journey includes postdoctoral training in nanoengineering and cancer research, followed by six years as an Assistant Professor at Kansas State University. At UT-Tyler, his Aryal Lab develops innovative nanomedicines to address challenges in drug delivery, such as immune system compatibility and tumor targeting. His research is supported by grants from the National Science Foundation (NSF) and National Institutes of Health (NIH).

Key research themes include nanoparticle-biomaterial interface studies, paramagnetic imaging agents, and combinatorial drug delivery systems. He has published extensively on topics like liposomal formulations, graphene-based nanocomposites, and enzyme-responsive drug release mechanisms. His work bridges engineering and medicine, aiming to translate nanotechnology into clinical solutions for unmet medical needs.

Dr. Aryal's laboratory also explores physiologically based pharmacokinetic modeling to predict nanoparticle behavior in vivo, ensuring safe and effective clinical translation. His contributions to biomimetic nanoparticles and targeted therapies have advanced understanding of nanoparticle-cell interactions and imaging-guided cancer treatments.